Testicular germ cell tumours (TGCTs) are the most common cancer in young men. Here we perform whole exome sequencing of 42 TGCTs to comprehensively study the mutational profile of TGCT. The mutation rate is uniformly low in all of the tumours (mean 0.5 mutations per megabase [Mb]) as compared to the common cancers, consistent with the embryological origin of TGCT. In addition to expected copy number gain of chromosome 12p and mutation of KIT we identify recurrent mutations in the tumour suppressor gene CDC27 (11.9%). Copy number analysis reveals recurring amplification of the spermatocyte development gene FSIP2 (15.3%) and a 0.4Mb region at Xq28 (15.3%). Two treatment-refractory patients are shown to harbour XRCC2
INTRODUCTION
Testicular Germ Cell Tumours (TGCTs) are the most common cancer affecting young men with a mean age at diagnosis of 36 years 1,2 . The main TGCT histologies are seminomas, which resemble undifferentiated primary germ cells and non-seminomas, which show differing degrees of differentiation. Cure rates for TGCT are generally high, due to the sensitivity of malignant testicular germ cells to platinum-based chemotherapies, however this is at the cost of an increased risk of metabolic syndrome, infertility and secondary cancer [3] [4] [5] . Furthermore, there are limited options for the patients who are platinum resistant, a group for whom the long-term survival rate is poor 6 .
Overall TGCTs are markedly aneuploid with recurring gain of chromosomes 7, 8, 21, 22 and X [7] [8] [9] [10] [11] [12] [13] . In addition, gain of chromosomal material from 12p is noted in virtually all cases [7] [8] [9] with genomic amplification and overexpression of genes in the 12p11.2-p12.1 region reported in ~10% of TGCTs 14 . KRAS is located in this region has been proposed as the candidate driver 14 . Focused studies of TGCTs have identified somatic missense mutations and amplifications of the oncogene KIT, present in ~25% of seminomas 15, 16 . These reported mutations are clustered in the juxta membrane and kinase encoding domains of KIT 15, 16 . However, a study of 518 other protein kinase encoding genes failed to identify any new driver mutations 17 . Beyond these focused interrogations of specific genes, no systematic mutational analysis across all genes in a large series of TGCT samples has been reported to our knowledge.
Here we perform whole-exome sequencing (WES) of a series of 42 TGCTs to characterize the mutational signature of these tumours and to search for additional driver mutations and pathways disrupted. Our analyses demonstrate these tumours to be relatively homogeneous in profile with a markedly low rate of non-synonymous mutations and provide some novel insights into the genomic architecture of this biologically interesting tumour type.
RESULTS

Overview of TGCT mutational landscape
The 42 TGCT cases comprised 16 seminomas, 18 non-seminomas, 4 mixed seminoma/nonseminoma histology and 4 tumours of indeterminant classification. Fresh frozen tumour tissue and matched germline blood samples were obtained from each patient and whole exome sequencing (WES) was performed on extracted DNA, achieving mean coverage of 72× across targeted bases with 86% of targeted bases being covered at ≥20. Sequencing was conducted using Ilumina technology, with subsequent alignment, mapping, and variant calling performed using BWA/Stampy/GATK/MuTect software. Across all 42 cases a total of 1,168 somatic single nucleotide variants (SNVs) (795 non-synonymous), and 111 smallscale somatic insertion-deletions (indels) were identified equating to a mean rate of 0.51 somatic mutations per megabase (Mb). By comparison, recent large scale analysis across 27
cancer types recorded mean rates as high as 11.0/Mb in melanoma and 8.0/Mb in lung cancers with a mean rate across all tumour types of 4.0/Mb 18 , some eight times higher than that seen here in TGCT. Indeed the mutation rate in TGCT is within the second lowest decile, only marginally greater than paediatric cancers such as Ewing sarcoma (0.3/Mb) and Rhabdoid tumour (0.15/Mb). This observation is entirely consistent with oncogenic origins of TGCT arising during embryonic development 19 . Of additional note is the high intrapatient homogeneity in mutation rate present in our data, with a standard deviation of just 0.24 across the 42 tumours and the extreme lowest to extreme highest mutation rate varying by only one order of magnitude. This variation is low compared to the three orders of magnitude inter-sample variation observed for acute myeloid leukaemia (AML), which has a comparable mutation rate 18 . Of note, there were no genes that were recurrently mutated or structural variants shared between the tumours in which the mutational rate was >2 standard deviations above the mean (two tumours). The mutational spectrum of SNVs in the TGCTs was typified by an excess of CG>TA transitions (27% of SNVs), as observed in most solid tumours 18, 20 (figure 2). In addition TA>CG transitions (23%) as well as CG>AT transversions (31%, of which the majority were C>A) were also over-represented. While C>A transversions are observed at higher proportion in lung cancers postulated to be due to exposure to tobacco carcinogens 18 , this pattern is also has also been reported in melanoma, neuroblastoma and chronic lymphocytic leukemia 21 .
Driver genes
We used MutSigCV version 1.4 18 to identify genes harbouring more non-synonymous mutations than expected by chance given gene size, sequence context and gene-specific background mutation rates 18 . As expected KIT was identified as the most significantly mutated gene (figure 1), with mutations seen in 14.3% across all TGC tumours, but predominantly found in seminomas (31.3%); a result consistent with previously reported observations 16, 22 . All of the six KIT mutations we identified were in hotspot domains -five nonsynonymous SNVs in exon 17 (kinase encoding domain) and one in exon 11 (juxta membrane domain). The absence of another gene ranked above KIT is a notable result; given our study assesses an exome-wide compliment of genes. In addition to KIT, a nonsynonymous SNV was also observed in previously proposed TGCT driver gene KRAS. While p53 has been suggested to be a feature of TGCT 23 , none were observed in our dataset, consistent with most recent studies 17, 24, 25 . We validated all KIT/KRAS mutations called by NGS using Sanger sequencing of the respective exons across all samples and to ensure no additional mutations were missed. In all cases Sanger sequencing was 100% concordant with NGS.
In addition to KIT and KRAS there was an over-representation of mutations in CDC27 (cell division cycle 27) (11.9%; 5 mutations, 5 tumours) and PRKRIR (4 mutations, 2 tumours), neither of which have been previously reported as TGCT drivers. CDC27 is a core component of the anaphase-promoting complex/cyclosome (APC/C), a multi-subunit E3 ubiquitin ligase that governs cell cycle progression, through ubiquitination and degradation of G1/mitotic checkpoint regulators 26 . APC/C recruits its substrates via one of two adaptor proteins CDC20 or CDH1, overexpression of which have been linked to multiple tumours [27] [28] [29] . CDC27 is down-regulated in breast cancer and CDC27 is postulated to be a tumour suppressor 30 . All of the CDC27 mutations we identified were missense variants, characterised by a consistently low frequency of mutant allelic reads (8%-14%), consistent with CDC27 mutation being present only in a subclone of each tumour sample. Intriguingly subclonal low frequency of CDC27 mutation has also recently been demonstrated in a colonic adenocarcinoma 31 .
Pathway analysis
To increase our ability to identify cancer drivers and delineate associated oncogenic pathways for TGCT we incorporated mutation data from multiple tumour types using Oncodrive-fm 32 as implemented within the IntOGen-mutations platform 33 . The most frequently mutated pathways were those involved in metabolism (mutated in 93%), pathways in cancer (54%), endocytosis (54%) and PI3K-Akt signalling (54%). The most significantly mutated pathway was RNA degradation (14.6%), with a biased accumulation of functional mutations (fm-bias, P= 3.8×10 −3 ), observed across six different genes (see methods and Supplementary Table 2 ).
Copy number variation
The 42 tumours were analysed for copy number variation (CNV) using software package ExomeCNV 34 . Focal CNVs (up to 3Mb) were identified in all tumours and large-scale CNVs (≥3Mb) were detected in 35 (83%) tumours, (figure 3). Across all 42 cases the proportion of the tumour genome showing CNV ranged from 0.1% to 48.4% per genome (mean 10.8%). The most frequent large-scale chromosome abnormality was 12p copy number gain, present in 30 of the 42 tumours (71%), of which 25 were 12p isochromosomes, a result consistent with previous experimental observations [7] [8] [9] . The remaining 12 cases without large scale 12p gain all showed evidence of focal copy number amplification of 12p, however detailed analysis of these sub-regions did not reveal any recurring hotspots. Other recurring large-scale copy number changes included gain of chromosome X (16 cases, 38%) as well as gains of chromosomes 7 (n=15; 36%), 21 (n=12; 29%) and 22 (n=11; 26%), findings again consistent with previous studies [7] [8] [9] [10] [11] [12] [13] . Additionally we observed large scale copy number deletion of chromosome Y (10 cases, 24%). We used previously generated chromosomal comparative genomic hybridization (CGH) data for 24 of the tumours 12, 35, 36 to validate our large-scale CNVs for the known mutational event at 12p; concordance between NGS/CGH was 92%.
In terms of focal events three tumours (patients 115, 53, and 43) exhibited a high degree of chromosomal instability, with a 19-fold increase in focal alterations compared to the others. We assessed these cases for evidence of chromothripsis, which we defined as greater than 20 CNVs on a chromosome single arm. Whilst this technical definition was met for several loci, the majority of events were spread uniformly across the genome with no common hotspots across the three tumours. Excluding these three tumours we undertook an analysis of the focal alterations seen in the remaining 39 tumours to identify any recurrent patterns. Mapping the coordinates of all focal copy number events to genes all possible gene alterations were assessed, quality filtered and ranked by frequency (table 1 and methods). The highest ranking gene from this analysis was FSIP2 (fibrous sheath interacting protein 2) at 2q32.1, with 7 recurring amplifications observed across 6 (15.3%) tumours. FSIP2 amplifications were all 8-9kb in length spanning a sub-region of the gene coding sequence, encompassing exons [16] [17] . Recent functional evidence has demonstrated that part-gene amplifications do affect gene expression levels, with an effect size comparable to that of full-gene amplification 37 . Our finding of recurrent FSIP2 amplification is corroborated by recent high resolution SNP array data on an independent series of seminomas 38 , which documented FSIP2 amplification in 22% of tumours. Across both studies FSIP2 is the only gene consistently observed with focal amplification in >10% of cases. There is a strong biological basis for abnormalities of FSIP2 being a feature of TGCTs a priori. The fibrous sheath is a cytoskeletal structure located in the principle piece region of the sperm flagellum. Transcription of FSIP2 begins in late spermatocyte development with mouse model data demonstrating it to be expressed exclusively in the testis 39 . Furthermore, FSIP2 also binds to another fibrous sheath enzyme AKAP4 (A kinase (PRKA) anchor protein 4), which has been linked to male infertility 40 . Interestingly the tumour from patient 21, which harboured a FSIP2 amplification, also carried a missense mutation in AKAP4.
Other focal events observed included a 0.4Mb region at Xq28, with amplification in 6 cases. This region contains 18 genes, including TEX28 (testis expressed 28) and TKTL1 (transketolase like gene 1), both of which are overexpressed in the human testis 41 . TKTL1 is hypothesised to play a role in tumour response to hypoxia with increased TKTL1 expression correlating with poor patient outcome in many solid tumours 42 .
Clinicopathological-molecular associations
SNV/indel somatic mutation rates between seminoma and non-seminoma cases were almost identical; 0.50 and 0.49 mutations/Mb respectively. KIT mutations were observed predominantly in seminoma cases, as previously reported. The proportion of the genome showing CNV was elevated (+47%) in non-seminona tumours. A correlation between somatic mutational rate and patient age was seen (r=0.36), with the mean rate for patients aged over 40 years being 0.69 compared to 0.48 for cases under 40 (P=0.05, two-sided Student's t-test). This is consistent with a model in which the majority of mutations are passenger mutations that accumulate with patient age following the early in utero oncogenic transformation of germ cells. Of particular clinical interest is the mutational profile of treatment refractory TGCT, a rare subset of ~3% of patients in whom there is disease progression despite platinum-based chemotherapy. Within our cohort only one such patient, 40, had this profile of therapeutic response, so any conclusions are speculative. Accepting this caveat the mutational rate for this tumour was 0.49/Mb, a rate comparable to the overall cohort, and of the 18 SNVs identified in this patient (see Supplementary Table 1 ) a mutation in gene XRCC2 (c.6T>Gp.Cys2Trp) is of particular note. XRCC2 encodes a member of the RecA/Rad51-related protein family which participates in homologous recombination maintaining chromosome stability and repair of DNA damage. Importantly XRCC2 mutant animal clones show increased resistance to cisplatin through enhanced DNA repair activity 43 and XRCC2 germline variants have been shown to significantly associate with cytotoxic resistance in breast cancer 44 . In addition to the treatment refractory patient in our main cohort, we also performed exome sequencing of tumour DNA from one additional platinum refractory case (germline DNA was not available, patient 109), identifying a further mutation in XRCC2 (c.2T>Gp.Met1Arg). This additional variant had alternative allele frequency of only 4%, making it difficult to validate by Sanger. Both XRCC2 mutations are predicted to be pathogenic on the basis of in silico analysis using the CONDEL algorithm (CONsensus DELeteriousness (CONDEL) score of non-synonymous single nucleotide variants (SNVs), http://bg.upf.edu/fannsdb/help) 45, 46 .
DISCUSSION
Our exome analysis has confirmed mutation of KIT and recurrent copy number gain of 12p as archetypical features of TGCT. We have also characterised the mutational signature of TGCTs, demonstrating a homogeneous profile with a markedly low SNV mutation rate, consistent with the embryonic origins of the disease. This low rate of point mutations (i.e. SNVs) is contrasted however by frequent large scale copy number gains, of not only 12p but also chromosomes 7, 21, 22 and X. Since our study was empowered to identify recurrent mutations having frequency of >15% (84% power) we can conclude that it is unlikely that additional high frequency driver mutations will exist.
We did however identify novel mutations in the probable tumour suppressor gene CDC27, implicating CDC27 mutation as a potential oncogenic factor in a subset of TGCTs. Functionally CDC27 interacts with spindle checkpoint proteins encoded by MAD2 47 and TEX14 48 genes, the latter of which resides in a linkage disequilibrium (LD) block associated through recent genome wide association study (GWAS) with germline TGCT predisposition 49 . Interestingly three of the other TGCT GWAS risk loci contain genes also related to mitotic spindle assembly, MAD1L1, CENPE and PMF1 49, 50 . Collectively such observations provide further evidence of commonality between germline and somatic TGCT pathways, a notable result given the previous precedent that KITLG, the ligand which binds KIT, is the strongest existing TGCT GWAS risk locus (OR~2.5) 51 . Aside from CDC27 we also observed mutations in several other genes at a frequency of <10%; at this lower frequency our study was not sufficiently powered to comprehensively evaluate the genetic mutational profile (our power to detect mutations with frequencies <10% was 55%, at <5% only 14%).
Previous CGH studies have characterised the aneuploidy nature of TGCTs, and our findings are consistent with these analyses. We hypothesised that NGS exome data, with average probe lengths of ~200bp, would allow identification of novel small scale CNVs below the level detectable by CGH. We performed this analysis and identified recurring focal copy number alterations in the spermatocyte development gene FSIP2, a finding corroborated by previous independent orthologous study. Meta-analysis of the two experiments shows this to to be significant at p = 6.8×10 −9 . FSIP2 is shown to be unique to spermatogenic cells and is hypothesised to act as a linker protein, binding AKAP4 to the fibrous sheath 39 . Dysplasia of the fibrous sheath and mutations in AKAP4 have both been linked to male infertility 52, 53 , an established risk factor for TGCT 54 . The additional observation of an AKAP4 missense mutation further implicates this pathway, although the exact mechanisms facilitating tumourigenesis remain to be elucidated. Furthermore we observed recurrent deletion of chromosome Y, a finding that also has interesting resonance with the germline as chromosome Y "gr/gr" germline deletions are linked to both TGCT predisposition and male infertility 55, 56 . We additionally identified a recurring focal amplification of 0.4Mb in length at Xq28, a region encompassing 18 genes, several of which may plausibly link to TGCT. Several observations implicate chromosome X in germ cell oncogenesis, with family studies suggesting a possible X-linked model of inheritance for TGCT genetic susceptibility 57 . In addition, patients with Klinefelter syndrome (47XXY constitutional karyotype) have a 67-fold elevated risk of developing mediastinal germ cell tumours 58 .
We found no significant difference observed in the mutational rate between seminoma and non-seminoma cases. This is consistent with findings from germline genetic studies of TGCT, where no differential genotype risk has been observed between histological subgroups 49, 51, 59 . This supports a hypothesis of commonality in the oncogenic pathways activated, with differentiation occurring later in the tumour formation. This hypothesis is further supported by the observation of TGCT cases with mixed pathology 60 as well as bilateral and familial cases displaying tumours with inconsistent histological types 61, 62 . Descriptive analysis of a single treatment-refractory patient in our cohort revealed a XRCC2 mutation, a DNA repair gene which has been demonstrated to promote cisplatin resistance in animal studies 43 . Further analysis of one additional treatment-refractory tumour sample revealed some evidence for a second XRCC2 mutation. Cell line studies suggest that the exceptional sensitivity of TGCTs to cisplatin is due to their inability to repair treatment induced DNA damage, due to the low expression of DNA repair genes such as ERCC1 63 . In addition cisplatin resistant embryonal carcinoma cell lines show sensitivity to poly(ADPribose) polymerase (PARP) inhibition, through blocking their acquired ability to repair DNA 64 . The observation of XRCC2 mutations in our patient tumour data expands on these previous animal and cell line studies, further supporting an important role for this pathway.
To our knowledge this study represents the largest comprehensive sequencing study of TGCT conducted to date. While we have implemented strategies to accurately identify the mutational landscape of this tumour, we were only well powered to identify genes with high mutational frequency. Hence further insights into the biology of TGCT should be forthcoming through additional sequencing initiatives and meta-analyses of such data. This is likely to be especially important given the importance of probable histological subtypespecific changes, the subclonal architecture of TGCT and differences that are likely to be seen in platinum resistant tumours.
METHODS
Sample description
Samples were collected from TGCT patients at the Royal Marsden Hospital NHS Trust, UK. Informed consent was obtained from all participants and the study was approved by the Institute of Cancer Research/Royal Marsden Hospital Committee for Clinical Research (study number CCR2014) The samples have been previously reported in other studies 10, 12, 36, 62, 65 . Surgical specimens were snap-frozen within 30 minutes of surgery and matched blood samples were collected at time of surgery. Tumour samples were trimmed to remove surrounding normal tissue and tumour cells were confirmed by histological assessment. Tumour and matched lymphocyte DNA extracted by standard techniques 66, 67 . Tumour samples from patients 26 and 9 were obtained post chemotherapy. Clinical characteristics of our sample cohort were representative of the broader patient population, in terms of histological sub-types, patient age, familial TGCT and response to treatment. Our series was however enriched for cases with bi-lateral disease (9/42 cases in our series compared to a frequency of ~5% in the broader patient population).
Whole exome sequencing
Samples were quantified using Qubit technology (Invitrogen, Carlsbad, California, USA) and sequencing libraries constructed from 50ng of respective normal/tumour DNA. Library preparation was performed using 37Mb Nextera Rapid Capture Exome kits (Ilumina, San Diego, California, USA), with enzymatic tagmentation, indexing PCR, clean-up, pooling, target enrichment and post-capture PCR amplification/quality control performed in-house, following standardised protocols as per manufacturer guidelines. Samples underwent paired end sequencing using the Ilumina HiSeq2500 platform with a 100-bp read length. Mean coverage of 73.6× and 69.0× were achieved across targeted bases for tumour and normal samples respectively. FASTQ files were generated using Illumina CASAVA software (v. 1.8.1, Illumina) and aligned to the human reference genome (b37/hg19) using BurrowsWheeler Aligner (BWA, v. 0.5.10, http://bio-bwa.sourceforge.net/)/Stampy (v.1.0.23) packages. PCR-duplicates were removed and coverage metrics calculated using Picard-tools (v.1.48, http://picard.sourceforge.net/). Coverage metrics demonstrated a mean of 95% of target bases achieved >10× coverage and 86% >20×. The Genome Analysis Toolkit (GATK, v. 3.1-1, http://www.broadinstitute.org/gatk/) was used for local indel realignmen/base quality score recalibration and single nucleotide variations (SNVs) were called using MuTect (v. 1.1.4). Data was quality filtered using in house FoxoG software to remove potential artefactual variants introduced through DNA oxidation 21 . FoxoG ensured variants were supported by minimum of 1 alternative read in each strand direction, a mean Phred base quality score of > 26, mean mapping quality ≥50 and an alignability site score of 1.0. Small-scale insertion/deletions (Indels) were called using GATK.
We used MutSigCV (v.1.4) to identify genes somatically mutated more often than would be expected by chance 18 , after first excluding common germline SNPs with minor allele frequency > 25% as recorded in either dbSNP (http://www.ncbi.nlm.nih.gov/SNP/) or in our in-house data from exome sequencing of the UK 1958 birth cohort (Houlston et al., personal communication). In total 33 common germline SNP variants were removed across all samples. MutSigCV was run using the standard genominc covariates of (i) global gene expression data, (ii) DNA replication time and (iii) HiC statistic of open vs. closed chromatin states. We used Oncodrive-fm 32 as implemented within the IntOGen-mutations platform 68 , using data mutation data from multiple tumour studies (http://bg.upf.edu/group/ projects/oncodrive-fm.php; http://www.intogen.org/analysis/mutations/)
Confirmation sequencing
Confirmation sequencing was performed with bidirectional Sanger sequencing of KIT (exons 11, 17) and KRAS (exon 2) across all 84 tumour/normal samples. Primer sequences are shown in Supplementary Table 3 . Mutational analysis was conducted using Mutation Surveyor (v.3.97, SoftGenetics,100 Oakwood Ave, State College, PA, USA).
Copy number variation analysis
Copy number variation (CNV) analysis was conducted using the CRAN package ExomeCNV 34 , a statistical algorithm designed to detect CNV and loss of heterozygosity (LOH) events using depth-of-coverage and B-allele frequencies (https:// secure.genome.ucla.edu/index.php/ExomeCNV_User_Guide). ExomeCNV is calibrated to achieve high levels of sensitivity and specificity, with a power to detect of 95% for CNVs down to 500bp in length 34 . When recently tested using a matched tumour/normal exome dataset with ~40× coverage, ExomeCNV achieved 97% specificity and 86% sensitivity compared to results from Illumina Omni-1 SNP array 34 . To calculate CNVs, we first generated coverage files using GATK, then used ExomeCNV to calculate log coverage ratios between matched tumour/normal samples and make CNV calls per exon. Exonic CNV calls were combined into segments using circular binary segmentation. LOH calls were made by first identifying all heterozygous germline positions per case, using Platypus(v. 0.5.2) for germline variant calling. GATK was then used to create BAF files per case and ExomeCNV used to call LOH at heterozygous positions individually and at combined LOH segments.
CNV results were classified as large-scale (>3Mb in length) or focal (<3Mb) and filtered by coverage ratio selecting copy number gain >1.3 or loss <0.7, retaining calls with a specificity confidence score of 1.0. Focal events were analysed by gene, mapping the coordinates of all events to gene coding start and end points to assess all possible gene alterations. Small scale regions showing susceptibility to variable levels of coverage, i.e. exact same probes frequently altered and with both copy number gain and loss, were removed to avoid false-positive associations.
Pathway analysis
Pathway analysis was performed using Oncodrive-fm 32 as implemented within the IntOGenmutations platform 68 , using the 1,168 SNVs and indel mutations called across the 42 tumours.
Statistical analyses
Statistical significance of mutations were determined by testing whether the observed mutation counts in a gene significantly exceeded the expected counts based on a gene specific background mutation rate, as implemented in MutSigCV (v.1.4). Plotted in the far section of figures 1 are the resulting −log10(P-values), with the dotted red line denoting a significance threshold of P = 0.05 and the solid red line a genome wide significance threshold of P = 5×10 −6 . Due to the overall low frequency of mutations observed in our dataset and no genes were significant at the genome wide level, not even previously known TGCT driver gene KIT. Power analysis was conducted using a binomial power model, based on recent methods published by the Cancer Genome Analysis group at the Broad Institute 69 , incorporating the average background somatic mutation rate for a specific tumour, sample size and assuming a genome wide significance level of P ≤5×10 −6 . Significance of focal copy number events by gene were calculated under a binomial distribution. Meta-analysis was conducted using the Fisher method of combining P values from independent tests. Statistical analysis were carried out using R3.0.2 (http://www.r-project.org/) and Stata12 (StataCorp, Lakeway Drive College Station, Texas, USA) software. Continuous variables were analysed using Student's t tests. We considered a P-value of 0.05 (two-sided) as being statistically significant. The top bars represent somatic mutation rate per sample for the 42 samples (synonymous and non-synonymous (including small scale indels)). The genes listed on the right are mutated genes as prioritised by MutSigCV, ranked by −log 10 (p-value) (far right), with the dotted red line denoting a significance threshold of P=0.05 and the solid red line a genome wide significance threshold of 5×10 −6 (see Methods). Below the top ranked genes in a separate box are other notable but non-significant mutations. Mutations by sample are depicted in the central box, with colour indicating mutation type as per the legend. The far left bars represent the absolute number of mutations observed per gene across all samples and adjacent to this is the % of samples this represents.
